An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

• Status: Terminated
• Trial end date: 2017-06-14

Summary

Purpose of the study is to determine the following in patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.

• the safety and tolerability of ASP8273.

• the pharmacokinetics (PK) of ASP8273.

• the antitumor activity of ASP8273.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Mitogens; Naquotinib